AstraZeneca, Handa reach $51.4 million settlement in US antitrust case over Seroquel XR
MLex Summary: AstraZeneca and Handa have agreed to pay $51.4 million to resolve direct purchasers' US antitrust claims over an alleged reverse payment concerning Seroquel XR. The deal is subject to...To view the full article, register now.
Already a subscriber? Click here to view full article